6TH BIENNIAL SCIENTIFIC MEETING
MALAYSIAN ASSOCIATION for the STUDY of PAIN 2018

THEME: DELIVERING BETTER RELIEF FOR CANCER PAIN

17TH TO 18TH MARCH 2018

NATIONAL CANCER INSTITUTE
PUTRAJAYA, MALAYSIA

CONFERENCE VENUE:
NATIONAL CANCER INSTITUTE
No. 4, Jalan FY, Precinct 7,
62250 W. P. Putrajaya,
Malaysia

CONFERENCE SECRETARIAT:
MALAYSIAN ASSOCIATION for the STUDY of PAIN
Department of Anesthesiology,
University Malaya Medical Center
50603. Kuala Lumpur, Malaysia
Tel: +603 7950 2052
Fax: +603 7955 6705
Email: massecretariat@gmail.com
Website: www.masp.org.my
ABSTRACT

Persistence Patterns of Opioid Use over Three Follow-Up Years: The Difference between Non-cancer and Cancer Pain

Asween Rowena Sani1, Che Suraya Zin1, Abdul Halid Mohamed1, Mufrida Izzat1, Tan Heng Ling2, and Ng Kim Swan1

1International Islamic University Malaysia, Kuantan, Pahang, Malaysia.
2Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.
3Hospital Selangor, Selangor, Malaysia.

Background: This study examined the persistence patterns of opioid use in patients with non-cancer and cancer pain over three follow-up years.

Methods: Prescriptions issued between 1 January 2013 and 31 December 2015 were examined. Persistent opioid users were defined as wide, intermediate, or strict. Wide definition refers to patients prescribed >0.7DDD or >16.7mg morphine equivalents (MME) for at least 3 quarters of a year, intermediate definition refers to patients prescribed >1 DDD or 12.3 MME per day in a year, and strict definition refer to patients prescribed >2 DDD or 49.3 MME per day in a year. Patients who did not meet any of the definitions were categorized as non-persistent. The proportions of each definition over a 3-year follow-up period were calculated. All analyses were stratified into non-cancer and cancer groups and were performed using Stata 13.

Results: The proportion of non-persistent opioid users were higher in non-cancer (86%) and cancer (94%) groups compared to persistent opioid users. Proportions of persistent opioid users in the wide, intermediate, and strict definitions who continued opioid treatment until the end of follow up period were 19% (n=2/21), 43% (n=3/7), and 25% (n=1/4) in the non-cancer group, and were 6% (n=2/31), 0% (n=0/3), and 17% (n=1/6) in the cancer group, respectively.

Conclusion: Patients in the intermediate and strict definitions were most likely to continue opioid treatment over a 3-year period in non-cancer and cancer groups, respectively. Future work in a large-scale study is required to determine factors related to persistence patterns explored which is important for improving pain management.